In the online version of the article section 8 (Obesity), para 6, lines 1 to 5 which read as: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, of the GLP1-RA semaglutide 3 mg administered weekly and the combination of naltrexone and bupropione. should read: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, the GLP1-RA liraglutide 3 mg administered daily or semaglutide 2.4 mg administered weekly and the combination of naltrexone and bupropione. In online version of the article Section 8 (Obesity), table (New recommendation), third point which reads as: Medications for weight loss in obese subjects, including orlistat, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. should read: Medications for weight loss in obese subjects, including orlistat, liraglutide, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. The original article has been corrected.
Correction to .updated recommendations on cardiovascular prevention in 2022: an executive document of the italian society of cardiovascular prevention / Volpe, M.; Gallo, G.; Modena, M. G.; Ferri, C.; Desideri, G.; Tocci, G.; Bellone, S.; Bertolotti, M.; Biffi, A.; Consoli, A.; Corsini, A.; Nati, G.; Pirro, M.; Rubattu, S.; Trimarco, B.; de Kreutzenberg, S. V.; Volpe, R.. - In: HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION. - ISSN 1120-9879. - 29:2(2022), pp. 103-103. [10.1007/s40292-022-00508-7]
Correction to .updated recommendations on cardiovascular prevention in 2022: an executive document of the italian society of cardiovascular prevention
Gallo G.;Ferri C.;Desideri G.;Tocci G.;
2022
Abstract
In the online version of the article section 8 (Obesity), para 6, lines 1 to 5 which read as: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, of the GLP1-RA semaglutide 3 mg administered weekly and the combination of naltrexone and bupropione. should read: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, the GLP1-RA liraglutide 3 mg administered daily or semaglutide 2.4 mg administered weekly and the combination of naltrexone and bupropione. In online version of the article Section 8 (Obesity), table (New recommendation), third point which reads as: Medications for weight loss in obese subjects, including orlistat, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. should read: Medications for weight loss in obese subjects, including orlistat, liraglutide, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. The original article has been corrected.File | Dimensione | Formato | |
---|---|---|---|
Volpe_Correction_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
439.44 kB
Formato
Adobe PDF
|
439.44 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.